Coordinated Cellular Neighborhoods Orchestrate Antitumoral Immunity at the Colorectal Cancer Invasive Front.
CODEX
FFPE
antitumoral immunity
cellular neighborhoods
colorectal cancer
immune checkpoints
immune tumor microenvironment
multiplexed imaging
tertiary lymphoid structures
tissue architecture
Journal
Cell
ISSN: 1097-4172
Titre abrégé: Cell
Pays: United States
ID NLM: 0413066
Informations de publication
Date de publication:
03 09 2020
03 09 2020
Historique:
received:
29
07
2019
revised:
22
04
2020
accepted:
08
07
2020
pubmed:
9
8
2020
medline:
8
5
2021
entrez:
9
8
2020
Statut:
ppublish
Résumé
Antitumoral immunity requires organized, spatially nuanced interactions between components of the immune tumor microenvironment (iTME). Understanding this coordinated behavior in effective versus ineffective tumor control will advance immunotherapies. We re-engineered co-detection by indexing (CODEX) for paraffin-embedded tissue microarrays, enabling simultaneous profiling of 140 tissue regions from 35 advanced-stage colorectal cancer (CRC) patients with 56 protein markers. We identified nine conserved, distinct cellular neighborhoods (CNs)-a collection of components characteristic of the CRC iTME. Enrichment of PD-1
Identifiants
pubmed: 32763154
pii: S0092-8674(20)30870-9
doi: 10.1016/j.cell.2020.07.005
pmc: PMC7479520
pii:
doi:
Substances chimiques
B7-H1 Antigen
0
Biomarkers, Tumor
0
Types de publication
Journal Article
Research Support, N.I.H., Extramural
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
1341-1359.e19Subventions
Organisme : NIAID NIH HHS
ID : T32 AI007290
Pays : United States
Organisme : NIDDK NIH HHS
ID : UG3 DK114937
Pays : United States
Organisme : NIAID NIH HHS
ID : U19 AI100627
Pays : United States
Organisme : NHLBI NIH HHS
ID : R01 HL120724
Pays : United States
Organisme : NIAID NIH HHS
ID : U01 AI101984
Pays : United States
Organisme : NHGRI NIH HHS
ID : U54 HG010426
Pays : United States
Organisme : NCI NIH HHS
ID : F99 CA212231
Pays : United States
Organisme : NIAID NIH HHS
ID : U01 AI140498
Pays : United States
Organisme : NIAID NIH HHS
ID : U19 AI135976
Pays : United States
Organisme : NIAID NIH HHS
ID : P01 AI131374
Pays : United States
Organisme : NIAID NIH HHS
ID : U19 AI057229
Pays : United States
Organisme : NCI NIH HHS
ID : U2C CA233238
Pays : United States
Organisme : NCI NIH HHS
ID : F32 CA233203
Pays : United States
Organisme : NHLBI NIH HHS
ID : P01 HL108797
Pays : United States
Organisme : NCI NIH HHS
ID : U2C CA233195
Pays : United States
Organisme : NHLBI NIH HHS
ID : R01 HL128173
Pays : United States
Organisme : NCI NIH HHS
ID : R33 CA183692
Pays : United States
Organisme : NIAMS NIH HHS
ID : T32 AR007422
Pays : United States
Organisme : Cancer Research UK
ID : C27165/A29073
Pays : United Kingdom
Commentaires et corrections
Type : ErratumIn
Informations de copyright
Copyright © 2020 The Author(s). Published by Elsevier Inc. All rights reserved.
Déclaration de conflit d'intérêts
Declaration of Interests G.P.N. has received research grants from Pfizer, Vaxart, Celgene, and Juno Therapeutics during the course of this work. G.P.N., Y.G., and N.S. have equity in and are scientific advisory board members of Akoya Biosciences. C.M.S. is a scientific advisor to Enable Medicine. Akoya Biosciences makes reagents and instruments that are dependent on licenses from Stanford University. Stanford University has been granted US patent 9909167, which covers some aspects of the technology described in this paper.